Canadian company says its COVID-19 vaccine spurred ‘promising antibody response’ in Phase 1 of clinical trials
The Canadian company behind a new plant-derived COVID-19 vaccine candidate has released the results of their Phase 1 clinical trials, saying two doses of their adjuvanted vaccine spurred a significant antibody response in 100 per cent of the trial subjects.
